February 16, 2021
Indies Pharma Jamaica Limited reported revenue of $223.53 million, 15% higher than the $193.72 million booked in 2020.
Cost of Sales increased 30% to close at $85.42 million (2020: $65.86 million). Gross profit increased by 8%, amounting to $138.11 million for the period relative to $127.86 million in 2020.
Other operating income for the period declined by 70% to close at $209,621 (2020: $698,370).
Additionally, administrative and other expenses fell by 18%, moving from $91.78 million in 2020 to $74.89 million.
As such, operating profit increased by 72% from $36.78 million recorded in 2020 to $63.44 million for the quarter ended January 31, 2021. There was a finance costs of $15.58 million for the quarter ended January 2021 (2020: nil) “mainly due to the interest payment to Bond holders made the company to settle with 20% year on year growth in the net profit” according to INDIES. While foreign exchange loss amounted to $331.68 million from a gain of $2.83 million in 2020.
Profit before taxation increased by 20% to close the period at $47.53 million (2020: $39.61 million). INDIES incurred no taxes for the quarter, thus net profit amounted to $47.53 million (2020: $39.61 million). Total Comprehensive Income amounted to $47.53 million for the quarter ended January 31, 2021 relative to $39.61 million in 2020.
Consequently, earnings per share (EPS) for the quarter amounted to $0.04 compared with $0.03 for the corresponding period of last year. The trailing twelve months earnings per share amounted to $0.16. The numbers of shares used in the calculations are 1,332,536,649 units. Notably, INDIES stock price closed the trading period on March 15, 2021 at $3.16 with a corresponding P/E of 19.62 times.
Balance Sheet at a glance:
Assets totalled $1.76 billion as at January 31, 2021 relative to $927.29 million a year prior. The increase in total assets was largely due to a 372% surge in ‘Property, plant and equipment’ to total $1.16 billion (2020: $244.92 million).
Total shareholder’s equity amounted to $834.27 million (2019: $734.84 million) with book value per share amounting to $0.63 (2020: $0.55).
Disclaimer:
Analyst Certification -The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view (s) expressed by that research analyst in this research report.
Company Disclosure -The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.
